Novo Nordisk Fights Back with Oral GLP-1 Data in Obesity

Novo Nordisk fights back with oral GLP-1 data in obesity

Shortly after reporting weaker sales growth for its injectable GLP-1 drugs, Novo Nordisk has new data to help it stake a claim to the oral market

Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors

Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associated with improvements in blood sugar control and cardiovascular (CV) risk factors across multiple categories of weight

Novo Nordisk’s oral Wegovy reduces cardiovascular risk factors in obesity

Novo Nordisk has already submitted for approval of oral Wegovy in obesity with the FDA.

Semaglutide Reduces Fat Mass More Than Cagrilintide in Obesity Treatment Study

Recent findings presented at ObesityWeek indicate that […] The post Semaglutide Reduces Fat Mass More Than Cagrilintide in Obesity Treatment Study first appeared on GeneOnline News. The post Semaglutide Reduces Fat Mass More Than Cagrilintide in Obesity Treatment Study appeared first on GeneOnline News.